accelerate factor VIII clearance contribute to antibody pathogenicity in a murine hemophilia A model. J Thromb Haemost 2018;
• Inhibitor formation remains a challenging complication of hemophilia A care.
• The Bethesda assay is the primary method used for determining bleeding risk and management.
• Antibodies that block factor VIII binding to von Willebrand factor can increase FVIII clearance.
• Antibodies that increase clearance contribute to antibody pathogenicity.
Summary. Background: The development of neutralizing anti-factor VIII (FVIII) antibodies remains a challenging complication of modern hemophilia A care. In vitro assays are the primary method used for quantifying inhibitor titers, predicting bleeding risk, and determining bleeding management. However, other mechanisms of inhibition are not accounted for in these assays, which may result in discrepancies between the inhibitor titer and clinical bleeding symptoms. Objectives: To evaluate FVIII clearance in vivo as a potential mechanism for antibody pathogenicity and to determine whether increased FVIII dosing regimens correct the associated bleeding phenotype. mice. Anti-C1, anti-C2 and anti-A2 mAbs that do not inhibit VWF binding did not accelerate FVIII clearance.
Infusion of increased doses of FVIII in the presence of anti-C1 mAbs partially corrected blood loss in FVIII

Introduction
Hemophilia A is an X-linked inherited bleeding disorder defined by a deficiency or absence of coagulation protein factor VIII (FVIII). Individuals with this disorder may present with spontaneous or trauma-induced hemarthrosis, muscle bleeds, or intracranial hemorrhage [1, 2] . A complication of treatment is the development of neutralizing alloantibodies (i.e. inhibitors), which occurs in ∼ 30% of patients with severe hemophilia A [3] [4] [5] . The most widely used method for detecting an inhibitor and predicting bleeding risk is the Bethesda assay. The Bethesda assay is an in vitro one-stage clot-based assay that quantifies the inhibition of FVIII procoagulant activity by antibodies in inhibitor plasma [6] [7] [8] . However, the Bethesda assay has limitations [9] [10] [11] . The Bethesda assay does not account for a diverse spectrum of multidomain inhibitory and non-inhibitory anti-FVIII antibodies [7, 12, 13] , or the effect of these antibodies on FVIII binding to von Willebrand factor (VWF), activation of FVIII by thrombin, or FVIII clearance. For instance, we have reported that the Bethesda assay did not predict pathogenicity or response to FVIII in a subset of high-titer anti-A2 and anti-C2 antibodies [14, 15] . Additionally, antibodies that are characterized as low-titer inhibitors in the Bethesda assay may accelerate the clearance of FVIII. This can result in discrepancies between the inhibitor titer, the FVIII pharmacokinetic profile in the presence of the inhibitor, and the clinical bleeding phenotype.
In patients with hemophilia A and low-titer inhibitors, defined as a titer of < 5 Bethesda units (BU) mL
À1
, infusion of high doses of FVIII ranging from 50 units kg
to 200 units kg À1 is a strategy often utilized to prevent and treat bleeding symptoms [16, 17] . However, there are anecdotal reports of poor responses to FVIII in patients with low-titer inhibitors despite high-dose or frequentdosing factor regimens. In some cases, these patients have required immune tolerance induction (ITI) for inhibitor eradication or a bypassing agent to treat bleeding symptoms. In our previous study characterizing antibodies directed against the C1 domain of FVIII in a hemophilia A murine model, we found that weakly inhibitory antibodies induced bleeding in the tail snip bleeding assay after FVIII replacement [18] . Low-titer anti-C1 mAbs, specifically mAbs 2A9 and M6143, caused not only weak inhibition of FVIII but also incomplete (type 2) inhibition at saturating concentrations in the Bethesda assay. The pathogenicity of weakly inhibitory anti-C1 mAbs was hypothesized to result from increased clearance of the FVIII-mAb complex due to the inhibition of FVIII binding to VWF. The characteristics of these antibodies may explain the discordant inhibitor titers obtained with the Bethesda assay and tail snip bleeding phenotype in hemophilia A mice. In this study, we evaluated the contribution of FVIII clearance on the bleeding phenotype in FVIII -/-and FVIII -/-/VWF -/-mice. We postulate that increased clearance of the FVIII-mAb complex resulting from antibody disruption of the FVIII and VWF binding interaction is an important determinant of the pathogenicity of anti-FVIII antibodies.
Materials and methods
Materials
Murine anti-human C1, C2 and A2 mAbs were purified from anti-FVIII hybridomas as previously described [19, 20] . The human-derived anti-C1 mAb KM33 was previously received as a gift from J. Voorberg (Sanquin Research, Amsterdam, the Netherlands). The characteristics of the mAbs used in this study are summarized in Table 1 . Citrated pooled normal plasma (FACT) and FVIII-deficient plasma were purchased from George King Biomedical (Overland Park, KS, USA). B-domain-deleted FVIII was expressed and purified as previously described [21] [22] [23] . All other materials were reagent-grade or are described in the cited literature. (mg g À1 ) following tail snips was measured by use of a preweighed 15-mL conical tube containing normal saline. Predicted peak inhibitor titers of the antibodies used in this model were calculated from the Bethesda titer, mAb concentration, and estimated mouse plasma volume per average mouse weight.
FVIII activity and antigen levels FVIII activity and antigen levels were measured to evaluate FVIII clearance as previously described [18] . Briefly, mice were euthanized 15 min following FVIII injections, and plasma samples were collected by cardiac puncture. FVIII antigen levels were determined by ELISA as follows: Anti-A1 mAb 2-116 (6 lg mL
À1
) in phosphate-buffered saline/0.05% sodium azide was coated on ELISA plates, incubated overnight at 4°C, and blocked. Serial dilutions of mouse plasma samples in 2-mercaptoethanol (90 mM) were prepared on a polypropylene plate, and transferred to ELISA plates. FVIII, diluted to 1 lg mL
in FVIII-deficient plasma, was serially diluted in 2-mercaptoethanol on a separate polypropylene plate, and transferred to the ELISA plates to construct a standard curve. FVIII was detected with biotinylated anti-A2 mAb 2-76 (non-competing for anti-C1 mAbs) for anti-C1 mAbs or with anti-C1 mAb B136 (non-competing for anti-C2 or anti-A2 mAbs) for anti-C2 or anti-A2 mAbs and alkaline phosphate-conjugated streptavidin. There were no significant differences in the standard curve obtained using biotinylated anti-A2 mAb 2-76 compared to the standard curve obtained using biotinylated anti-C1 B136 for FVIII detection. FVIII antigen levels in mouse plasmas were quantified using the standard curve. FVIII procoagulant activity was measured using the activated partial thromboplastin reagent-based one-stage coagulation assay as previously described [25] and pooled FVIII À/À mouse plasma spiked with FVIII to 1 U mL À1 for the standard curve.
Statistical analysis
Data are presented as medians with interquartile ranges for blood loss in the tail snip bleeding model, or as means with standard deviations for FVIII activity and antigen levels. Significant differences in blood loss in the tail snip bleeding model were determined with the Mann-Whitney U-test, and significant differences in FVIII activity and antigen levels were determined with the Kruskal-Wallis test with Dunn's correction for multiple comparisons. The relationship between median blood loss and predicted peak inhibitor titer was determined with Pearson's correlation coefficient. Statistical analyses were performed with PRISM 6.0 (GraphPad Software, La Jolla, CA, USA). Differences in FVIII antigen levels in FVIII À/À mice that received anti-A2 or anti-C2 mAbs as compared with no mAb control starting at 30 min and concluding at 8 h were determined with non-linear regression to fit exponential decay models and the Sums of Squares Reduction test with the Bonferroni method for multiple comparisons (significance level, a = 0.007). A P-value of < 0.05 was considered to be statistically significant unless stated otherwise.
Results
High-dose FVIII replacement partially reduces bleeding in hemophilia A mice infused with anti-C1 mAbs
We have previously reported that anti-C1 mAbs 2A9, M6143, B136 and KM33 are pathogenic in a murine model [18] . In this model, the ability of FVIII to correct excessive bleeding following tail snip in FVIII À/À mice is tested in mice that have been injected with anti-FVIII mAbs. The inhibitory activity in the Bethesda assay of these mAbs ranged from weak to strong (23-3700 BU mg À1 ) ( Table 1 ). All four antibodies inhibited the binding of FVIII to VWF (Table 1) . Previous studies have reported that the abnormal bleeding produced by some inhibitory anti-A2 and anti-C2 mAbs could be overcome by increasing the FVIII dose [14, 15] . To determine whether abnormal bleeding could be corrected in mice injected with anti-C1 mAbs, blood loss was measured in the tail snip bleeding model in FVIII (Table 1) was not pathogenic in the presence of low-dose FVIII and thus not tested at high-dose FVIII. Incomplete correction of blood loss in FVIII À/À mice was positively correlated with the predicted peak inhibitor titer for anti-C1 mAbs in the presence of low-dose and high-dose FVIII ( Fig. 2A,B) , although the trend with high-dose FVIII did not reach statistical significance. These results may be attributable to the combined presence of antibodies that inhibit FVIII function and weakly inhibitory antibodies that accelerate FVIII clearance.
Very high doses of FVIII are required to reduce bleeding in FVIII À/À mice given the weakly inhibitory anti-C1 mAb
M6143
High-dose FVIII did not correct the blood loss in FVIII À/À mice that received the weakly inhibitory mAb M6143 compared to mice that received low-dose FVIII in the absence of antibody, although there was a trend towards reduction (Fig. 1) ) or highdose (360 units kg À1 ) FVIII (estimated peak plasma concentration of 2.5 nM or 5 nM, respectively). Tail snips were performed at 2 h after injection of FVIII, and blood loss was measured for 40 min or until death of the mouse. Data are presented as medians with interquartile ranges (n = 8-9 mice per group). Blood loss for each group was compared with that for FVIII À/À mice that received 2.5 nM FVIII in the absence of antibody by use of the Mann-Whitney U-test; *P < 0.05; **P < 0.01; ***P < 0.001. ( Fig. 3B) . [18] . Under these conditions, there were no significant differences in FVIII antigen levels between groups. However, FVIII activity was significantly reduced for groups M6143 and B136 compared to mice that received FVIII alone (Fig. 4A,B) . There was also a trend towards a reduction in FVIII activity in the 2A9 mAb group (Fig. 4B ) and in the M6143 and B136 mAb groups given 180 units kg À1 FVIII (Fig. 4D) . Carryover of the inhibitory activity of these antibodies in the FVIII activity assay may account for this discrepancy. However, because of the relatively large intragroup variation in the FVIII antigen assays (Fig. 4A) /VWF À/À mice (unpublished data). Data are presented as mean with standard deviation for FVIII antigen levels and activity (n = 3-8 mice per group). FVIII antigen levels and activities for each mAb group were compared to the FVIII-only group by Kruskal-Wallis tests with Dunn's correction for multiple comparisons; *P < 0.05; **P < 0.01; **P < 0.01. mechanisms dependent on VWF that could affect the bleeding phenotype induced by anti-FVIII antibodies.
Anti-FVIII mAbs directed against non-C1 domain VWF epitopes increase FVIII clearance in FVIII À/À mice
Previously we investigated the in vivo pathogenicity of antibodies against the A2 and C2 domains of FVIII [14, 15] . A subset of anti-A2 and C2 mAbs produced bleeding in FVIII À/À mice at low and high doses of FVIII (180 units kg À1 and 360 units kg
À1
, respectively) in the tail snip bleeding model. The in vivo pathogenicity of these mAbs was attributed to their inhibition of FVIII activity. Antibodies that inhibit the binding of FVIII to phospholipid inhibit FVIII procoagulant activity in vitro and produce a positive Bethesda titer. In contrast, antibodies that inhibit the binding of FVIII to VWF but not to phospholipid do not necessarily inhibit FVIII procoagulant activity in vitro. The in vitro effects of these antibodies on anti-FVIII activity and inhibition of FVIII binding to VWF and phospholipid are summarized in Table 1 . Given the role of increased FVIII clearance produced by anti-C1 mAbs [18] , we investigated the effect of a subset of anti-A2 and C2 antibodies directed against immunodominant epitopes in human FVIII.
We measured plasma FVIII antigen levels at 0.5, 1, 2, 4 and 8 h in FVIII À/À mice following injection of anti-A2 mAb 4A4 or anti-C2 mAbs 3D12, I109, or 2-117. Anti-C2 mAbs 3D12 and I109, which inhibit the binding of FVIII to VWF and phospholipid, significantly increased FVIII clearance over a period of 8 h compared to mice that received FVIII alone (Fig. 5A,B) . However, the strongly inhibitory anti-A2 mAb 4A4 and the non-inhibitory anti-C2 mAb 2-117, neither of which inhibit FVIII binding to VWF or phospholipid, did not affect FVIII clearance. Additionally, two non-inhibitory anti-B mAbs that do not affect FVIII binding to VWF or phospholipid had no effect on FVIII clearance (data not shown). This suggests that the pathogenicity of both low-titer and high-titer anti-FVIII antibodies that compete with VWF for FVIII binding may be attributable, in part, to increased FVIII clearance. mAb), and 2-117 (anti-C2 mAb), followed by~180 units kg À1 FVIII in FVIII À/À mice. Differences in FVIII antigen levels in mAb groups 4A4 (P = 0.62), 3D12 (P < 0.001), I109 (P < 0.001) or 2-117 (P = 0.26) as compared with those in no-mAb controls starting at 30 min and concluding at 8 h were determined with non-linear regression to fit exponential decay models and the Sum of Squares Reduction test with the Bonferroni method for multiple comparisons (significance level, a = 0.007). (B) FVIII antigen levels 2 h after FVIII infusion are compared to mice that received FVIII alone by Kruskal-Wallis test with Dunn's correction for multiple comparisons. Data are presented as means with standard deviation (n = 3-7 mice per group); *P < 0.05; **P < 0.01; ***P < 0.001.
Discussion
In this study, we hypothesized that antibodies that inhibit FVIII binding to VWF increase the clearance of FVIII and contribute to antibody pathogenicity. Our prior work showed that the weakly inhibitory anti-C1 mAbs 2A9 and M6143 and the strongly inhibitory mAbs B136 and KM33, which inhibit FVIII binding to VWF, increased FVIII clearance and produced bleeding in FVIII À/À mice [18] . Additional studies have reported that the pathogenic bleeding phenotype produced by a subset of anti-A2 and anti-C2 mAbs that do not compete with VWF for FVIII binding could be reversed with increased FVIII doses [14, 15] . showed a significantly positive correlation with the predicted peak inhibitor titers in the presence of low-dose but not high-dose FVIII (Fig. 2 ). This suggests that some patients with a low-titer inhibitor may have a lower than expected hemostatic response, due to the presence of anti-FVIII antibodies that increase FVIII clearance. The partial correction of bleeding in FVIII À/À mice treated with anti-C1 mAbs was further explored by measuring dose-dependent blood loss in mice injected with increasing doses of FVIII and mAb M6143 at a peak concentration of 65 nM. Unexpectedly, mice required doses of FVIII up to 720 units kg À1 and 1440 units kg À1 (peak concentrations of 10 nM and 20 nM, respectively) for bleeding reduction following M6143 injection (Fig. 3) . mAb M6143 is a weakly inhibitory mAb that has an inhibitor titer of 180 BU mg À1 IgG, an estimated peak plasma inhibitor titer of 2.3 BU mL À1 at the dose used in this study, and a high-affinity dissociation constant for FVIII binding of 0.2 nM [18] . High doses of FVIII have been used clinically to achieve hemostasis in patients with non-amnestic low-titer inhibitors (defined as < 5 BU mL À1 ) by saturating the inhibitor [16, 17, 26, 27] .
Multiplying the plasma volume by the inhibitor titer has been reported as a formula for determining the number of FVIII units required to saturate the inhibitor and achieve hemostasis [26] . For instance, in the murine tail snip bleeding model 180 units kg À1 FVIII, corresponding to a peak plasma concentration of 2.5 nM, is the estimated dose required to saturate the inhibitor in a mouse injected with 0.5 mg kg À1 mAb M6143. However, FVIII À/À mice required more than twice this dose to reverse the bleeding phenotype (Fig. 3) . However, it remains unclear whether the inhibitory effect of mAbs in mouse plasmas correlates with the inhibitory effect in humans at the same Bethesda titer, or whether the definitions of low-titer and high-titer inhibitors used in patients are applicable in the mouse model. Although supraphysiological doses of FVIII were required to reverse bleeding in the tail snip bleeding model, the predicted plasma concentration of mAb M6143 was still in molar excess over FVIII. This correction of bleeding at substoichiometric concentrations of FVIII could result from VWF competition with the mAb for FVIII binding. This would favor formation of the FVIII-VWF complex at a hemostatically active FVIII dose that limits antibody pathogenicity. In contrast, at lower doses, FVIII is partitioned into rapidly cleared, hemostatically ineffective FVIII-mAb immune complexes. Additionally, FVIII clearance was not accelerated in FVIII À/À /VWF À/À mice in the presence of anti-FVIII mAbs (Fig. 4) . These results are consistent with competitive partitioning of FVIII between FVIII-VWF and FVIII-mAb complexes. Given the high binding affinity of FVIII for VWF (K d of 0.2 nM) [28] , the use of FVIII products prebound to VWF may be beneficial in some patients for the treatment of bleeding, due to competition between VWF and anti-FVIII antibodies directed against 'clearance' epitopes. Although increased FVIII doses reduced bleeding in mice that received a group of anti-A2 and anti-C2 mAbs in the tail snip bleeding model, a subset of these mAbs remained pathogenic at low and high doses of FVIII [14, 15, 29] . Their pathogenicity was attributed to inhibition of FVIII procoagulant function. However, classical anti-C2 mAbs also inhibit FVIII binding to VWF and do not respond to increased FVIII doses, suggesting that their pathogenicity is at least partly attributable to increased clearance of FVIII. Consistent with this hypothesis, anti-C2 mAbs 3D12 and I109, which inhibit VWF and phospholipid binding, accelerated FVIII clearance, in contrast to anti-A2 mAb 4A4 and anti-C2 mAb 2-117, which do not interfere with VWF or phospholipid binding (Fig. 5) . Thus, the inhibition of FVIII procoagulant activity may be sufficient to explain the pathogenicity of high-titer inhibitors. However, for some low-titer antibodies, FVIII clearance may result in greater pathogenicity than predicted by the Bethesda assay alone. This may explain why some patients with low-titer inhibitors have significant bleeding despite aggressive FVIII replacement. Some of these non-responding patients may require treatment with a bypassing agent or ITI for inhibitor eradication.
Although the A2 and C2 domains of FVIII are considered the predominant immunogenic epitopes, neutralizing and non-neutralizing antibodies against all of the domains within FVIII have been described in humans and mice, as detected by ELISA and chromogenic-based assays in addition to the one-stage clot-based Bethesda assay [20, [30] [31] [32] [33] . One group postulated that antibodies against non-neutralizing antibodies (defined by a negative Bethesda titer but a high anti-FVIII ELISA titer) in patients with hemophilia may accelerate the clearance of infused FVIII [34] . A separate study examining different methods for inhibitor detection described a group of seven patients with congenital hemophilia A and low-titer inhibitors defined by a Nijmegen Bethesda titer of < 2.0 NBU and a positive chromogenic Bethesda assay result [35] . Three of these patients with low-titer inhibitors maintained their response to FVIII replacement therapy, whereas four patients required treatment with a bypassing agent and/or ITI. Another study reported a linear relationship between the concentration of porcine FVIII required to produce in vitro recovery to 50% of normal and the anti-porcine FVIII inhibitor titer, suggesting that an inhibitor neutralization assay may be more sensitive and quantitative than the Bethesda assay [7] . Laboratory assays that account for antibody characteristics such as antibody binding affinity, epitope specificity and the effects on FVIII biochemical properties and clearance not addressed by the Bethesda assay could help to optimize the management of patients with inhibitors.
This work underscores the importance of understanding the underlying mechanisms of FVIII clearance, the role of VWF in FVIII procoagulant function and clearance in the setting of antigen-antibody immune complexes, and the epitope-specific pathogenicity of anti-FVIII antibodies. It suggests that there are distinct clearance pathways of FVIII and the FVIII-VWF complex in the presence and absence of anti-FVIII inhibitors. Several receptors have been shown to bind FVIII, VWF, or both, and contribute to FVIII clearance or endocytosis in circulation, including receptors that bind to the low density lipoprotein (LDL), lecithin and scavenger receptor families [36] . For instance, the clearance receptor LDL-related protein receptor, a member of the LDL receptor family, has demonstrated binding to FVIII as a ligand via the C2 domain and is downregulated by VWF [37] . Whether different classes of anti-FVIII inhibitors differentially modulate clearance receptors is not known. Additionally, the clearance of FVIII immune complexes by Fc receptors or other mechanisms is not understood.
In this study, we show that anti-FVIII mAbs directed against various FVIII epitopes that compete with VWF for FVIII binding increase the clearance of FVIII-mAb immune complexes, and contribute to antibody pathogenicity. In-depth investigation of the critical FVIII clearance pathways involved in the presence and absence of inhibitors and the contribution of VWF could provide greater insight into the mechanisms that determine the pathogenicity of anti-FVIII antibodies in patients. The development of laboratory methods that account for the effect of anti-FVIII antibodies on FVIII biology may complement current methods used to quantify anti-FVIII antibodies and help guide the determination of optimal treatment regimens. Addendum G. Batsuli designed and performed research, analyzed data, and co-wrote the paper. J. Ito, R. Mercer, W. H. Baldwin, C. Cox, E. T. Parker, and J. F. Healey performed research. S. L. Meeks and P. Lollar analyzed data and co-wrote the paper.
